Lori A Leslie
Overview
Explore the profile of Lori A Leslie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
1048
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ip A, Kabat M, Fogel L, Alkhatatneh H, Voss J, Gupta A, et al.
Cancers (Basel)
. 2025 Feb;
17(4).
PMID: 40002289
Advancements in mantle cell lymphoma (MCL) have illuminated the disease's molecular diversity, leading to a wide variation in the outcomes observed in MCL. Current prognostic risk scores are continuously revised...
2.
Samples L, Sadrzadeh H, Frigault M, Jacobson C, Hamadani M, Gurumurthi A, et al.
Blood
. 2025 Feb;
PMID: 39938007
Burkitt lymphoma (BL) is an aggressive B-cell lymphoma associated with poor outcomes in patients with relapsed/refractory disease. This multicenter, retrospective study evaluated real-world CD19 CAR T-cell therapy outcomes in patients...
3.
Corona M, Ip A, Brown S, Luna A, Khatib H, Flynn J, et al.
Bone Marrow Transplant
. 2025 Feb;
PMID: 39893244
CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy has recently been approved as second-line treatment for relapsed/refractory large B-cell lymphoma (LBCL). This study compares patterns of disease relapse and progression across...
4.
Ghosh N, Eyre T, Brown J, Lamanna N, Manzoor B, Coombs C, et al.
Am J Hematol
. 2024 Dec;
100(3):511-515.
PMID: 39698781
No abstract available.
5.
Lorenc R, Shouval R, Flynn J, Devlin S, Saldia A, Luna de Abia A, et al.
Transplant Cell Ther
. 2024 Jul;
30(10):990-1000.
PMID: 38972512
Chimeric antigen receptor (CAR) T cells are an established treatment for B cell non-Hodgkin lymphomas (B-NHL). With the remarkable success in improving survival, understanding the late effects of CAR T...
6.
Benjamini O, Fried S, Shouval R, Flynn J, Beyar-Katz O, Leslie L, et al.
Haematologica
. 2024 Jun;
109(11):3566-3577.
PMID: 38899351
The activity of anti-CD19 chimerci antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia (CLL) with Richter's transformation (RT) to aggressive large B-cell lymphoma (LBCL) is largely unknown. In a...
7.
Neelapu S, Chavez J, Sehgal A, Epperla N, Ulrickson M, Bachy E, et al.
Blood
. 2023 Oct;
143(6):496-506.
PMID: 37879047
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL). Approval was supported by the phase 2, multicenter, single-arm ZUMA-5...
8.
Ip A, Petrillo A, Della Pia A, Lee G, Gill S, Varughese T, et al.
Leuk Lymphoma
. 2023 Sep;
64(14):2225-2235.
PMID: 37740588
Mantle cell lymphoma (MCL) is a rare non-Hodgkin lymphoma that frequently becomes chemoresistant over time. The distinct mechanisms of ibrutinib and lenalidomide provided a judicious rationale to explore the combination...
9.
Scordo M, Flynn J, Gonen M, Devlin S, Parascondola A, Tomas A, et al.
Blood Adv
. 2023 Jul;
7(18):5579-5585.
PMID: 37522731
Fludarabine is one of the most common agents given for lymphodepletion before CD19 chimeric antigen receptor T cells, but its optimal therapeutic intensity is unknown. Using data from a multicenter...
10.
Westin J, Oluwole O, Kersten M, Miklos D, Perales M, Ghobadi A, et al.
N Engl J Med
. 2023 Jun;
389(2):148-157.
PMID: 37272527
Background: In an analysis of the primary outcome of this phase 3 trial, patients with early relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel), an autologous anti-CD19...